186 related articles for article (PubMed ID: 35475762)
1. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD.
Cazzola M; Rogliani P; Calzetta L; Ora J; Matera MG
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):269-283. PubMed ID: 35475762
[TBL] [Abstract][Full Text] [Related]
2. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
3. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
5. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
[TBL] [Abstract][Full Text] [Related]
8. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
[TBL] [Abstract][Full Text] [Related]
9. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
10. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
11. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Ismaila AS; Risebrough N; Schroeder M; Shah D; Martin A; Goodall EC; Ndirangu K; Criner G; Dransfield M; Halpin DM; Han MK; Lomas DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2681-2695. PubMed ID: 31819401
[TBL] [Abstract][Full Text] [Related]
13. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
Mannino D; Bogart M; Wu B; Germain G; Laliberté F; MacKnight SD; Jung Y; Stiegler M; Duh MS
Respir Med; 2022 Jun; 197():106807. PubMed ID: 35429764
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
15. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Yang S; Lee LA; Sule N; Fowler A; Peachey G
Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225
[TBL] [Abstract][Full Text] [Related]
19. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
20. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]